Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.56 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | TTR | P02766 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1791487 | 0.92 | MAPT (0.75) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL3132340 | 0.90 | MAPT (0.87) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1792352 | 0.89 | MAPT (0.74) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL1792682 | 0.88 | MAPT (0.72) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL1790029 | 0.85 | MAPT (0.73) | MAPTMEN1KMT2AKDM4EPOLB | |
| SCHEMBL12292282 | 0.85 | MAPT (0.58) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL3142833 | 0.84 | MAPT (0.81) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL2305041 | 0.83 | MAPT (0.83) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL1792774 | 0.83 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EGAA | |
| SCHEMBL1793447 | 0.80 | MAPT (1.00) | MAPTMEN1KMT2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642584-B2 | Method of using PI3K and MEK modulators | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | EXELIXIS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | MAPT 3587/4885MEN1 3161/4885KMT2A 2013/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885MEN1 1310/4885KMT2A 1063/4885 |
| US-20110207712-A1 | Phosphatidylinositol 3-Kinase Inhibitors And Methods Of Their Use | PIK3CA, PIK3CB, PIK3CG | MAPT 3587/4885MEN1 3161/4885KMT2A 2013/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | MAPT 4580/4885MEN1 1310/4885KMT2A 1063/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | MAPT 4242/4885MEN1 1197/4885KMT2A 1079/4885 |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | ERBB2, EGFR, ERBB3 | MAPT 1653/4885MEN1 2255/4885KMT2A 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.